This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts See a 75.05% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 75.1% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After Plunging -10.7% in 4 Weeks, Here's Why the Trend Might Reverse for HUTCHMED (HCM)
by Zacks Equity Research
HUTCHMED (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for HUTCHMED (HCM) points to a 107.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 141.13%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for HUTCHMED (HCM) points to a 141.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts See a 103.84% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 103.8% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About HUTCHMED (HCM) Rating Upgrade to Buy
by Zacks Equity Research
HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think HUTCHMED (HCM) Could Surge 102.73%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 102.7% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Down -25.73% in 4 Weeks, Here's Why HUTCHMED (HCM) Looks Ripe for a Turnaround
by Zacks Equity Research
HUTCHMED (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 61.85%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for HUTCHMED (HCM) points to a 61.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does HUTCHMED (HCM) Have the Potential to Rally 68.08% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Hutchison China MediTech (HCM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Hutchison China MediTech (HCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hutchison China MediTech (HCM) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Hutchison China MediTech (HCM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Can the Rally in HUTCHMED (HCM) Shares Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of HUTCHMED (China) Limited (HCM).
Here's Why "Trend" Investors Would Love Betting on Hutchison China MediTech (HCM)
by Zacks Equity Research
Hutchison China MediTech (HCM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Moving Average Crossover Alert: Hutchison China MediTech (HCM)
by Zacks Equity Research
Hutchison China MediTech (HCM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Hutchison China MediTech (HCM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Hutchison China MediTech (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moving Average Crossover Alert: Hutchison China MediTech
by Zacks Equity Research
Hutchison China MediTech Limited (HCM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Hutchison China MediTech Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Hutchison China MediTech.
Hutchison China MediTech (HCM) Is Up 0.6% in One Week: What You Should Know
by Zacks Equity Research
Does Hutchison China MediTech (HCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hutchison China MediTech Solutions Enters Oversold Territory
by Zacks Equity Research
Hutchison China MediTech has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Top Ranked Momentum Stocks to Buy for September 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 16th